JP2022549892A5 - - Google Patents

Info

Publication number
JP2022549892A5
JP2022549892A5 JP2022519283A JP2022519283A JP2022549892A5 JP 2022549892 A5 JP2022549892 A5 JP 2022549892A5 JP 2022519283 A JP2022519283 A JP 2022519283A JP 2022519283 A JP2022519283 A JP 2022519283A JP 2022549892 A5 JP2022549892 A5 JP 2022549892A5
Authority
JP
Japan
Prior art keywords
sequence
aav vector
vector according
seq
pgrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519283A
Other languages
English (en)
Japanese (ja)
Other versions
JP7854715B2 (ja
JP2022549892A (ja
Filing date
Publication date
Priority claimed from GB201913974A external-priority patent/GB201913974D0/en
Application filed filed Critical
Publication of JP2022549892A publication Critical patent/JP2022549892A/ja
Publication of JP2022549892A5 publication Critical patent/JP2022549892A5/ja
Application granted granted Critical
Publication of JP7854715B2 publication Critical patent/JP7854715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519283A 2019-09-27 2020-09-28 ベクター Active JP7854715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913974A GB201913974D0 (en) 2019-09-27 2019-09-27 Vector
GB1913974.0 2019-09-27
PCT/EP2020/077144 WO2021058830A1 (en) 2019-09-27 2020-09-28 Vector

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066254A Division JP2026133380A (ja) 2019-09-27 2026-04-14 ベクター

Publications (3)

Publication Number Publication Date
JP2022549892A JP2022549892A (ja) 2022-11-29
JP2022549892A5 true JP2022549892A5 (cg-RX-API-DMAC7.html) 2023-10-12
JP7854715B2 JP7854715B2 (ja) 2026-05-07

Family

ID=68538788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519283A Active JP7854715B2 (ja) 2019-09-27 2020-09-28 ベクター

Country Status (8)

Country Link
US (1) US12680109B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034664A1 (cg-RX-API-DMAC7.html)
JP (1) JP7854715B2 (cg-RX-API-DMAC7.html)
CN (3) CN119913208A (cg-RX-API-DMAC7.html)
AU (1) AU2020354538A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155742A1 (cg-RX-API-DMAC7.html)
GB (1) GB201913974D0 (cg-RX-API-DMAC7.html)
WO (1) WO2021058830A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913974D0 (en) 2019-09-27 2019-11-13 King S College London Vector
EP4384195A2 (en) * 2021-08-11 2024-06-19 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
CN116064624A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rpl基因促进载体稳定表达的方法及其功能基因
WO2024245120A1 (en) * 2023-05-26 2024-12-05 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating proteinopathies in central nervous system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
US7071172B2 (en) * 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
JP5123936B2 (ja) 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
US20130090374A1 (en) 2011-04-20 2013-04-11 Miguel Sena-Esteves Methods for the treatment of tay-sachs disease, sandhoff disease, and gm1-gangliosidosis
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
JP6738728B2 (ja) * 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
EP3632923A1 (en) * 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
CA3016314A1 (en) 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
EP3692158A4 (en) * 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
CN118345115A (zh) 2017-12-01 2024-07-16 编码治疗公司 工程化的dna结合蛋白
KR102171360B1 (ko) * 2018-06-22 2020-10-28 재단법인대구경북과학기술원 사이토카인 융합 폴리펩티드, 및 이를 포함하는 사이토카인 라이브러리
CA3125770A1 (en) * 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
MX2021010134A (es) * 2019-02-22 2021-09-23 Univ Pennsylvania Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
CA3162618A1 (en) * 2019-03-20 2020-09-24 Peter Jungsoo PARK Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
TW202111127A (zh) 2019-07-24 2021-03-16 美商航海家醫療公司 用於治療亨丁頓舞蹈症之組合物及方法
GB201913974D0 (en) 2019-09-27 2019-11-13 King S College London Vector

Similar Documents

Publication Publication Date Title
BR112020006786A2 (pt) composições e métodos para editar rna
US10494619B2 (en) High isomerohydrolase activity mutants of human RPE65
US20230227802A1 (en) Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2016150964A1 (en) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
JP2024543918A (ja) Aadc、gdnfポリヌクレオチド及びそのパーキンソン病を治療するための使用
CA3169529A1 (en) Compositions and methods for the treatment of metabolic liver disorders
CN104936606A (zh) 糖原贮积病的基因疗法
JP2022093334A (ja) アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物
KR20230123460A (ko) Neurod1 벡터
US20240175054A1 (en) Composition and methods for the treatment of fabry disease
TW202507008A (zh) 用於治療與葡萄糖神經醯胺酶β1缺陷相關之病症的組合物及方法
JP2023520402A5 (cg-RX-API-DMAC7.html)
CN115927412A (zh) 密码子优化的补体因子i
US20220339183A1 (en) Treatment of tauopathies
JP2025503910A5 (cg-RX-API-DMAC7.html)
JP2024505081A (ja) 神経変性疾患を治療するための遺伝子療法
CN116670291A (zh) 用于神经退行性疾病的基因疗法
CN116656704B (zh) 用于治疗法布里病的转基因表达盒
WO2022187671A1 (en) Compositions and methods for the treatment of hemophilia
US20250361527A1 (en) Vector-based gene therapy for elongator acetyltransferase complex subunit 1 (elp1)
KR20250143161A (ko) 시누클레인병증의 치료를 위한 유전자 요법
WO2024079292A1 (en) Gene therapy treatment
IL294777A (en) gene therapy
WO2022059014A1 (en) Methods for treating alpha-synuclein-related diseases
CN116710566A (zh) Neurod1载体